Pharmacology Chemotherapy c6335c7a

Tildrakizumab was approved in March 2018 for

Psoriasis

HIV

Rheumatoid ahritis

Hepatitis C

High-Yield Explanation

Tildrakizumab was designed to block interleukin-23, a cytokine that plays an impoant role in managing the immune system and autoimmune disease. It is approved for the treatment of moderate-to-severe plaque psoriasis.Ref:

← Previous Question Next Question →

Related Pharmacology MCQs

Which of the following is glucocoicoid synthesis inhibitor?

General

At a high altitude of 3000 m, a person complains of breathlessness. All of the following can...

General

All of the following drugs act on cell membrane except:

General

A non-competitive inhibitor of an enzyme?

General

Which of the following is a phase I metabolic reaction?

General

Explore All Pharmacology Questions →

Tildrakizumab was approved in March 2018 for

Related Pharmacology MCQs

Practice 2,00,000+ NEET PG Questions Free